# CSPC PHARMACEUTICAL GROUP LIMITED
# 石藥集團有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

## QUARTERLY RESULTS
## FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024

The Board of Directors of CSPC Pharmaceutical Group Limited (the "Company") is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (the "Group") for the nine months ended 30 September 2024.

### FINANCIAL HIGHLIGHTS
*(in RMB'000, unless otherwise stated)*

| | Nine months ended 30 September | | |
|---|---|---|---|
| | **2024** | 2023 | Change |
| **Revenue by business units:** | | | |
| Finished drugs | **18,670,189** | 19,338,055 | -3.5% |
| Bulk products | **2,726,122** | 2,875,233 | -5.2% |
| Functional food and others | **1,289,840** | 1,651,788 | -21.9% |
| **Total revenue** | **22,686,151** | 23,865,076 | -4.9% |
| **Profit attributable to shareholders** | | | |
| Underlying profit *(Note)* | **3,998,789** | 4,715,187 | -15.2% |
| Reported profit | **3,778,039** | 4,494,641 | -15.9% |
| **Earnings per share** *(RMB cents)* | | | |
| Based on underlying profit attributable to shareholders | | | |
| — Basic | **33.90** | 39.69 | -14.6% |
| — Diluted | **33.90** | 39.69 | -14.6% |
| Based on reported profit attributable to shareholders | | | |
| — Basic | **32.03** | 37.84 | -15.4% |
| — Diluted | **32.03** | 37.83 | -15.3% |

*Note: Underlying profit attributable to shareholders, a non-HKFRS measure, represents reported profit attributable to shareholders before taking into account fair value changes on financial assets measured at fair value through profit or loss ("FVTPL"), employee share-based compensation expense and gain on deemed disposal of partial interest in an associate. Reconciliation between underlying profit and reported profit is provided on page 14 of this announcement.*

## RESULTS FOR THE FIRST NINE MONTHS OF 2024

Revenue amounted to RMB22,686 million, a decrease of 4.9% as compared to the same period last year. Mainly due to the decrease in revenue from the finished drug business, underlying profit attributable to shareholders decreased by 15.2% to RMB3,999 million as compared to the same period last year, while profit attributable to shareholders decreased by 15.9% to RMB3,778 million as compared to the same period last year.

## BUSINESS REVIEW

### Finished Drug Business

Revenue from the finished drug business decreased by 3.5% to RMB18,670 million for the period. Sales by major therapeutic areas are as follows:

| **Therapeutic Area** | **Sales** *(RMB' million)* | **Change** |
|---|---|---|
| Nervous system | 7,234 | +4.5% |
| Oncology | 3,809 | –17.6% |
| Anti-infectives | 3,211 | +2.2% |
| Cardiovascular | 1,631 | –11.1% |
| Respiratory system | 941 | –18.8% |
| Digestion and metabolism | 865 | +30.7% |
| Others | 979 | +2.6% |

Revenue from the nervous system therapeutic area decreased by 15.8% in the third quarter as compared to the same quarter last year. Nonetheless, revenue in this area for the period recorded an overall growth of 4.5% as compared to the same period last year. NBP (恩必普®) (butylphthalide soft capsules and butylphthalide and sodium chloride injection) experienced a significant sales decrease in the third quarter of this year primarily due to tightened controls being imposed on drugs highly ranked in terms of usage amid an environment where hospitals strictly controlled medical expenses. On the other hand, the sales of Mingfule (明復樂®) (recombinant human TNK tissue-type plasminogen activator for injection) recorded a satisfactory result during the period after obtaining the marketing approval of a new indication for the treatment of acute ischemic stroke patients in the beginning of this year.

Revenue from the oncology therapeutic area for the third quarter and the period decreased by 31.2% and 17.6% respectively as compared to the corresponding quarter and period last year. This is mainly because Jinyouli (津優力®) (PEG-rhG-CSF injection) and Duomeisu (多美素®) (doxorubicin hydrochloride liposome injection), with approximately 58% and 23% prices cut, respectively, at the volume-based procurement ("VBP") in the Beijing-Tianjin-Hebei "3+N" Alliance, experienced significant sales decline in the second and third quarters of this year following the gradual implementation of the VBP results in the related provinces since March this year. For new products, the sales of Duoenyi (多恩益®) (irinotecan hydrochloride liposome injection), Duoenda (多恩達®) (mitoxantrone hydrochloride liposome injection) and Geruite (戈瑞特®) (lenvatinib mesilate capsules) maintained high growth during the period.

Revenue from the anti-infectives therapeutic area decreased by 9.6% in the third quarter as compared to the same quarter last year. Nonetheless, revenue in this area for the period maintained stable growth as compared to the same period last year.

Revenue from the cardiovascular therapeutic area for the third quarter and the period decreased by 26.7% and 11.1% respectively as compared to the corresponding quarter and period last year. This is mainly because Xuanning (玄寧®) (maleate levamlodipine tablets and dispersible tablets) was not selected in the eighth batch of national VBP in 2023, causing a significant impact on sales from hospitals that strictly implemented the VBP. The decline was particularly notable in the second and third quarters of this year. Moreover, the sales of Encun (恩存®) (clopidogrel bisulfate tablets) and Yishuning (意舒寧®) (nifedipine controlled-release tablets) continued to grow during the period.

Revenue from the respiratory system therapeutic area for the third quarter and the period decreased by 35.1% and 18.8% respectively as compared to the corresponding quarter and period last year. During the period, the sales of Qixiao (琦效®) (arbidol hydrochloride tablets) recorded a significant decrease as driven by lowered market demand. Moreover, benefiting from effective promotion strategies and booming demand, the sales of Yiluoda (伊絡達®) (nintedanib capsules) and Nuoyian (諾一安®) (montelukast sodium tablets/chewable tablets) maintained satisfactory growth during the period.

Revenue from the digestion and metabolism therapeutic area decreased by 11.2% in the third quarter as compared to the same quarter last year. Nonetheless, revenue in this area for the period achieved significant growth by 30.7% as compared to the same period last year. Benefiting from effective promotion strategies and market demand, the sales of Oubeituo (歐倍妥®) (esomeprazole capsules) and Debixin (得必欣®) (omeprazole capsules/tablets/injection) increased notably.

**Bulk Product Business**

The sales of the bulk product business decreased by 5.2% to RMB2,726 million for the period. Mainly due to the decline in market demand, the sales of vitamin C products decreased by 3.4% to RMB1,462 million and the sales of antibiotic products decreased by 7.2% to RMB1,264 million.

**Functional Food and Other Businesses**

The sales of the functional food and other businesses decreased by 21.9% to RMB1,290 million for the period. Price of caffeine products remained stable during the period, but still showed a significant decline as compared to the same period last year.

**Research and Development**

During the period, R&D expenses increased by 5.5% to RMB3,880 million as compared to the same period last year, accounting for approximately 20.8% of the revenue from the finished drug business. Currently, more than 60 key drug candidates have entered clinical trial or registration stage, of which 6 candidates have filed marketing approval application and 24 products (30 indications) have entered pivotal clinical trial stage.

***Regulatory Updates***

Since the beginning of the year, 2 innovative drugs (additional indications), 1 biosimilar drug and 1 special preparation have obtained marketing approval, and drug candidates have obtained 34 clinical trial approvals and 7 generic drugs have obtained registration approvals in China. In North America, 3 innovative drug candidates have obtained clinical trial approval and 1 Fast Track Designation has been obtained.

*China*

- In February 2024, Mingfule (明復樂®) (recombinant human TNK tissue-type plasminogen activator for injection) (rhTNK-tPA) obtained marketing approval for the thrombolytic treatment in patients with acute ischemic stroke. It is the first approval for this indication of this product type in China, and the second approved indication of the product.

- In June 2024, Enshuxing (恩舒幸®) (recombinant fully human anti-PD-1 monoclonal antibody) obtained conditional marketing approval for the treatment of recurrent or metastatic cervical cancer patients with positive PD-L1 (CPS≥1) expression who have previously failed to respond to platinum-based chemotherapy.

- In September 2024, amphotericin B liposome for injection obtained marketing approval of the indications for the treatment of: 1) systemic fungal infections caused by susceptible fungi; 2) patients with neutropenia and unexplained fever who are highly suggestive of the presence of systemic fungal infections; and 3) visceral leishmaniasis in adults and children.

- In September 2024, Enyitan® (恩益坦®) (omalizumab for injection) obtained marketing approval as the first biosimilar drug of Xolair® (茚樂®) developed as Class 3.3 therapeutic biological product in China for the treatment of adults and adolescents (12 years of age and older) with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.

- 13 drug candidates have obtained clinical trial approval for their first indications and 21 additional indications have obtained clinical trial approval:

  *First Indication*

| **Drug Candidate** | **Indication** |
|---|---|
| JMT202 (mAb) | Lowering of triglyceride (TG) levels in patients with hypertriglyceridemia |
| SYS6023 (ADC) | Advanced solid tumors |
| SYH2039 (MAT2A) | Advanced malignant tumors |
| Dexmedetomidine hydrochloride nasal spray | Sedation before invasive procedures |
| Pilocarpine hydrochloride eye drops | Presbyopia |
| Pregabalin extended-release tablets | Neuropathic pain associated with diabetic peripheral neuropathy |
| Semaglutide injection | Weight management |
| SYS6020 injection (CAR-T) | Recurrent or refractory multiple myeloma |
| Aprepitant injection | Prevention of postoperative nausea and vomiting in adults |

| Drug Candidate | Indication |
|---|---|
| SYS6016 injection (mRNA vaccine) | Prevention of lower respiratory tract diseases caused by RSV infections |
| Dextromethorphan hydrobromide bupropion hydrochloride extended-release tablets | Adult depression |
| Tebipenem pivoxil fine granules | Community-acquired bacterial pneumonia in children |
| Valsartan levoamlodipine maleate tablets | Primary mild and moderate hypertension that cannot be effectively controlled by monotherapy |

*Additional Indication*

| Drug Candidate | Indication |
|---|---|
| SYSA1801 injection | In combination with CAPOX and SG001 or with irinotecan hydrochloride liposome injection for first-line and second-line treatment of Claudin18.2-positive gastric cancer |
| JMT101 injection | In combination with docetaxel (albumin-bound) for treatment of second-line and above EGFR lung squamous cell carcinoma |
| Simmitinib hydrochloride tablets | In combination with irinotecan liposome for the treatment of advanced esophageal cancer |
| Sirolimus for injection (albumin-bound) | In combination with endocrine therapy for the treatment of HR-positive HER2-negative advanced breast cancer after failure of standard therapy |
| Docetaxel for injection (albumin-bound) | In combination with glumetinib tablets for the treatment of locally advanced or metastasis non-small cell lung cancer with negative driver genes and MET overexpression in patients whose disease has progressed after recovery immunotherapy (anti-PD-1/PD-L1 antibody) and platinum-based doublet chemotherapy (in combination or sequential) |
| SYH2043 tablets | In combination with fulvestrant for the treatment of advanced breast cancer |
| Cisplatin micelle injection | In combination with paclitaxel for the treatment of advanced solid tumors |
| Octreotide long-acting injection | Gastroenteropancreatic neuroendocrine tumors |
| Irinotecan liposome injection | In combination with oxaliplatin and tegafur for adjuvant treatment after pancreatic cancer surgery |
| DP303c injection | In combination with simmitinib hydrochloride or irinotecan liposome for the treatment of HER2-expressing locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma |
| Simmitinib hydrochloride tablets | In combination with DP303c injection for the treatment of HER2 low-expressing recurrent/metastatic breast cancer |
| SYS6002 for injection (Nectin-4 ADC) | In combination with SG001 for the treatment of advanced solid tumors |
| SYHA1813 oral solutions | In combination with SG001 and docetaxel for injection (albumin-bound) for the treatment of advanced solid tumors |

| Drug Candidate | Indication |
|---|---|
| Sirolimus for injection (albumin-bound) | In combination with irinotecan liposome injection for the treatment of small cell lung cancer |
| SYS6020 injection (CAR-T) | Systemic lupus erythematosus |
| SYS6020 injection (CAR-T) | Myasthenia gravis |
| SYS6010 | In combination with osimertinib for the treatment of locally advanced or metastatic EGFR mutated non-small cell lung cancer |
| SYS6010 | In combination with SYH2051 tablets with or without bevacizumab for the treatment of advanced solid tumors |
| SYS6010 | In combination with SG001 with or without chemotherapy for the treatment of EGFR and ALK wild-type advanced non-small cell lung cancer and other advanced solid tumors |
| SYSA1801 injection | In combination with capecitabine for the treatment of first-line unresectable locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma |
| KN026 | Neoadjuvant therapy for early stage or locally advanced HER2-positive breast cancer in combination with HB1801 |

- Since the beginning of the year, 7 generic drugs have obtained drug registration approval, namely dapagliflozin tablets, peramivir injection, olaparib tablets, palbociclib tablets, roxadustat capsules, aprepitant injection and dexrazoxane for injection.

*North America*

- In January 2024, JMT106 injection (bispecific fusion protein targeting GPC3 and interferon receptors) obtained clinical trial approval in the US.

- In April 2024, SYH2039 tablets (MAT2A inhibitor) obtained clinical trial approval in the US.

- In July 2024, SYS6023 (ADC) obtained clinical trial approval in the US.

- In September 2024, CPO301 (EGFR-ADC) received Fast Track Designation from the US Food and Drug Administration (FDA) for the treatment of recurrent or metastatic squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) overexpression that has progressed on or after treatment with platinum-based chemotherapy and anti-PD-L1 therapy.

***Major Clinical Trials Progress***

***DP303c injection (recombinant humanised anti-HER2 monoclonal antibody-MMAE conjugate for injection)***

- In February 2024, the phase III clinical trial for the treatment of second-line and above HER2-positive advanced breast cancer was initiated in China. The study is currently in the enrollment stage.

***Daunorubicin cytarabine liposome for injection***

- In February 2024, the phase III clinical trial for the treatment of high-risk secondary acute myeloid leukemia (AML) in the elderly patients who have not been previously treated was initiated in China. The study is currently in the enrollment stage.

***Docetaxel for injection (albumin-bound)***

- In February 2024, the phase III clinical study comparing to Taxotere® for the treatment of locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma that has previously failed first-line treatments was initiated in China. The study is currently in the enrollment stage.

***Semaglutide injection***

- In August 2024, subject enrollment of the phase III clinical trial for the treatment of type 2 diabetes initiated in China was completed.

- In September 2024, subject enrollment of the Phase III clinical trial for weight management initiated in China was completed.

***JMT103 (narlumosbart injection)***

- In March 2024, the phase III clinical trial for the treatment of bone metastasis of malignant solid tumors was initiated in China. The study is currently in the enrollment stage.

***SYHX2011 (paclitaxel for injection (albumin-bound) II)***

- In March 2024, subject enrollment of the phase III clinical trial for the treatment of advanced breast cancer initiated in China was completed.

***Pregabalin extended-release tablets***

- In May 2024, the phase III clinical trial for neuropathic pain associated with diabetic peripheral neuropathy was initiated in China. The study is currently in the enrollment stage.

***Secukinumab injection***

- In June 2024, the phase III clinical trial comparing to Cosentyx® for the treatment of moderate-to-severe plaque psoriasis was initiated in China. The study is currently in the enrollment stage.

***TG103 injection (GLP-1 receptor agonist)***

- In January 2024, subject enrollment of the phase III clinical trial for the treatment of overweight and obesity initiated in China was completed.

- In April 2024, the phase III clinical study for the treatment of type 2 diabetes was initiated in China. The study is currently in the enrollment stage.

***JMT101 injection (recombinant humanised anti-epidermal growth factor receptor monoclonal antibody injection)***

- In April 2024, the phase III clinical trial of JMT101 in combination with osimertinib comparing to cisplatin in combination with pemetrexed for the treatment of NSCLC patients with first-line EGFR exon 20 insertion mutations was initiated in China. The study is currently in the enrollment stage.

***SYSA1902 (ustekinumab injection)***

- In September 2024, a phase III clinical study for the treatment of moderate-to-severe plaque psoriasis in China reached its predefined endpoint.

***Mitoxantrone hydrochloride liposome injection***

- In September 2024, subject enrollment of the phase III confirmatory clinical trial for the treatment of second-line and above relapsed/refractory peripheral T-cell lymphoma initiated in China was completed.

***Publication of Major Clinical Trial Results***

***SYS6002 for injection (anti-Nectin-4 monoclonal antibody-drug conjugate)***

- In January 2024, the results of a phase I clinical study for the treatment of advanced solid tumors were presented at the 2024 ASCO-GU Conference (No. B622). Preliminary results indicated that SYS6002 demonstrated clear efficacy signals and good tolerability in advanced solid tumors such as cervical cancer and urothelial carcinoma.

- In May 2024, the results of a phase I clinical study for the treatment of advanced solid tumors were presented in a poster session at the 2024 ASCO Conference (No. 3151). Preliminary results indicated that SYS6002 demonstrated clear efficacy signals and good tolerability in patients with advanced solid tumors.

***DBPR108 (prusogliptin tablets)***

- In January 2024, the results of a phase III clinical study of the monotherapy for the treatment of diabetes were published in the international journal *Diabetes, Obesity & Metabolism*, demonstrating that DBPR108 tablets had significantly better hypoglycemic efficacy than the placebo group and was non-inferior to the active group of sitagliptin phosphate tablets. In addition, the safety profile of DBPR108 tablets was similar to the placebo group and the active group of sitagliptin phosphate tablets.

***Duentai (SARS-CoV-2 mRNA vaccine)***

- From February 2024 to March 2024, multiple clinical study results of the first-generation COVID-19 mRNA vaccine were published in international journals *Emerging Microbes & Infections, Vaccine* and *Journal of Medical Virology*, respectively, demonstrating that the vaccine had good protective efficacy, immunogenicity and safety profile, with certain protection against XBB mutant strains.

- In March 2024, the results of a phase I clinical study of the bivalent COVID-19 mRNA vaccine (XBB.1.5/BQ.1) (SYS6006.32) were published in the international journal *Vaccine*, demonstrating that the vaccine had a good safety profile and immunogenicity, with cross-immunity against multiple mutant strains.

***JMT101 injection (recombinant humanised anti-epidermal growth factor receptor monoclonal antibody injection)***

- In March 2024, the results of a phase II clinical trial of JMT101 in combination with osimertinib for the treatment of locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutations (BECOME) were orally presented at the European Lung Cancer Congress 2024 (2024 ELCC), demonstrating the high potential efficacy and a manageable safety profile of JMT101 in combination with osimertinib in NSCLC patients with EGFR exon 20 insertion mutations.

***TG103 injection (GLP-1 receptor agonists)***

- In April 2024, the results of a phase Ib clinical study of the monotherapy for overweight or obesity without type II diabetes were published in the international journal *BMC Medicine*. The study results indicated that the weight-reducing efficacy of TG103 monotherapy was significantly better than the placebo group.

***SG001 (enlonstobart injection)***

- In May 2024, the results of a phase Ib clinical study of SG001 monotherapy for recurrent or metastatic cervical cancer were published in the international journal *Cancer Communications*. The study results indicated that SG001 monotherapy demonstrated good efficacy with a manageable safety profile, and that it had great potential for future combination treatments in recurrent or metastatic cervical cancer.

- In May and October 2024, the results of a phase II clinical study of SG001 monotherapy for recurrent or metastatic cervical cancer were presented in a poster session at the 2024 ASCO Annual Conference (No. 5526) and published in the international journal *Gynecologic Oncology*, respectively. The study results indicated that SG001 monotherapy demonstrated durable anti-tumor activity and an acceptable safety profile in patients with PD-L1 positive recurrent/metastatic cervical cancer.

***Simmitinib hydrochloride tablets***

- In May 2024, the results of a phase I clinical study of simmitinib hydrochloride tablets for the treatment of advanced solid tumors were presented in a poster session at the 2024 ASCO Annual Conference (No. 3109). Preliminary study results indicated that simmitinib hydrochloride tablets had a controllable safety profile and demonstrated good efficacy in patients with esophageal squamous cell carcinoma.

***JMT103 (narlumosbart injection)***

- In May 2024, the results of a phase Ib clinical study of JMT103 for the treatment of bone metastasis of solid tumors were presented online at the 2024 ASCO Annual Conference (No. e15190). Preliminary study results indicated that JMT103 had low immunogenicity and a good safety profile, and demonstrated good efficacy in reducing biomarkers of bone metabolism.

***Docetaxel for injection (albumin-bound)***

- In May 2024, the results of a phase II clinical study of docetaxel albumin for the treatment of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma were presented online at the 2024 ASCO Annual Conference (No. e16018). Preliminary study results indicated that docetaxel albumin had a controllable safety profile and demonstrated good efficacy in patients with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

***DP303c injection (recombinant humanised anti-HER2 monoclonal antibody — MMAE conjugate for injection)***

- In August 2024, the results of a phase I clinical study of DP303c for the treatment of HER2-expressing advanced solid tumors were published in the international journal *npj Precision Oncology*. The study results indicated that DP303c demonstrated good efficacy in HER2-expressing advanced solid tumors, particularly in HER2-expressing breast cancer.

***SYHA1813 oral solutions***

- In September 2024, the results of a Phase I clinical study of SYHA1813 for the treatment of recurrent or advanced solid tumors were presented as mini-oral presentation at the ESMO Congress 2024 (No. 2032). The study results indicated that SYHA1813 had good anti-tumor efficacy in recurrent gliomas.

***KN026 injection***

- In September 2024, the results of a phase II clinical study of KN026 combination therapy for HER2-positive advanced unresectable or metastatic gastric cancer/gastroesophageal conjugate adenocarcinoma were presented in poster display session at the ESMO Congress 2024 (No. 1425P). The study results indicated that KN026 combination therapy demonstrated excellent efficacy, with a good safety profile, for the treatment of patients with second-line and above HER2-positive gastric cancer/gastroesophageal conjugate adenocarcinoma.

***CM310 injection***

- In September 2024, the results of a phase II clinical study of CM310 for the treatment of moderate-to-severe asthma were presented as poster session (No. 2982) and oral presentation (No. OR-0170) at the European Respiratory Society (ERS) Congress 2024 and the 2024 Annual Meeting of the Chinese Society of Allergy (CSA 2024), respectively. The study results indicated that CM310 significantly improved lung function and reduced acute asthma exacerbations and loss of control, especially in the 150 mg dose group. CM310 was also well tolerated and safe, with a low incidence of treatment-emergent adverse events (TEAE), mainly respiratory infections.

***NBL-012 injection (anti-IL 23 p19 subunit antibody)***

- In September 2024, the results of a Phase I clinical study of NBL-012 in healthy human subjects were presented in a poster session at the 2024 European Academy of Dermatology and Venereology Congress (EADV Congress) (No. P0959). The study results indicated that NBL-012 was overall safe and well tolerated in healthy subjects in China, showing linear pharmacokinetics in the dose range of 20 mg to 400 mg.

***SYHX1901 tablets***

- In September 2024, the results of a Phase II clinical study of SYHX1901 for moderate-to-severe plaque psoriasis were presented in poster session at the 2024 EADV Congress (No. P3135). The study results indicated that all three dose groups of SYHX1901 showed significantly better PASI75 than the placebo group at 12 weeks of treatment, with good overall safety and tolerability.

***Clinical Pipeline Overview***

*Registration and Pivotal Trial Stage*

| Drug candidate | Type | Target | Indication(s) | Status |
|---|---|---|---|---|
| DBPR108 (Prusogliptin tablets) | Chemical drug | DPP-4 inhibitor | Type 2 diabetes | Marketing approval application submitted |
| Meloxicam nanocrystal injection | Nanodrug | Selective COX-2 inhibitor | Moderate-to-severe pain in adults | Marketing approval application submitted |
| Amphotericin B liposome for injection | Nanodrug | Anti-infective, nonspecific drug | Invasive fungal infection | Marketing approval application submitted (US) |
| Irinotecan hydrochloride liposome injection | Nanodrug | Topoisomerase inhibitor | Pancreatic cancer | Marketing approval application submitted (US) |
| Clevidipine butyrate injectable emulsion | Nanodrug | Calcium channel blocker | Hypertension | Marketing approval application submitted |

| Drug candidate | Type | Target | Indication(s) | Status |
|---|---|---|---|---|
| Batoclimab (HBM9161) | Biological drug (monoclonal antibody) | FcRn | Myasthenia gravis | Marketing approval application submitted |
| DP303c injection (recombinant humanised anti-HER2 monoclonal antibody — MMAE conjugate injection) | Biological drug (ADC) | HER2 receptor (ADC) | Breast cancer | Pivotal trial |
| JMT101 injection (recombinant humanised anti-epidermal growth factor receptor monoclonal antibody injection) | Biological drug (monoclonal antibody) | EGFR | Non-small cell lung cancer/lung squamous cell carcinoma | Pivotal trial |
| KN026 injection | Biological drug (bispecific antibody) | HER2 bispecific antibody | Gastric cancer/Breast cancer/Neoadjuvant therapy for breast cancer | Pivotal trial |
| Pertuzumab injection | Biological drug (monoclonal antibody) | HER2 | Breast cancer | Pivotal trial |
| TG103 injection | Biological drug (monoclonal antibody) | GLP-1 receptor agonist | Obesity and overweight/ diabetes | Pivotal trial |
| CM310 injection | Biological drug (monoclonal antibody) | Anti-IL-4Rα monoclonal antibody | Asthma | Pivotal trial |
| SYSA1902 (ustekinumab injection) | Biological drug (monoclonal antibody) | IL-12/IL-23p40 | Psoriasis | Pivotal trial |
| SYHX2011 (paclitaxel for injection (albumin-bound) II) | Nanodrug | Microtubule inhibitor | Breast cancer | Pivotal trial |
| Daunorubicin cytarabine liposome for injection | Nanodrug | RNA/DNA polymerase inhibitor | Leukemia | Pivotal trial |
| Docetaxel for injection (albumin-bound) | Nanodrug | Microtubule inhibitor | Gastric cancer/ Pancreatic cancer | Pivotal trial |
| Semaglutide injection | Chemical drug | GLP-1Ra/GLP-1 receptor agonist | Diabetes/Weight management | Pivotal trial |
| Mitoxantrone hydrochloride liposome injection | Nanodrug | Cell-cycle nonspecific drug | Nasopharyngeal cancer | Pivotal trial |
| JMT103 (Narlumosbart injection) | Biological drug (monoclonal antibody) | RANKL | Bone metastasis of malignant solid tumors | Pivotal trial |

| Drug candidate | Type | Target | Indication(s) | Status |
|---|---|---|---|---|
| Pregabalin extended-release tablets | Chemical drug | γ-GABA analogue | Neuropathic pain associated with diabetic peripheral neuropathy | Pivotal trial |
| Pilocarpine hydrochloride eye drops | Chemical drug | Cholinergic muscarinic agonist | Presbyopia | Pivotal trial |
| Secukinumab injection | Biological drug (monoclonal antibody) | IL-17 monoclonal antibody | Psoriasis | Pivotal trial |
| SYHX1901 tablets | Chemical drug | JAK&SYK dual-target inhibitor | Psoriasis | Pivotal trial |
| Aprepitant injection | Chemical drug | NK-1 receptor antagonist | Prevention of postoperative nausea and vomiting | Pivotal trial |
| Sirolimus for injection (albumin-bound) | Nanodrug | mTOR inhibitor | Perivascular epithelioid cell tumor (PEComa) | Pivotal trial |
| Irinotecan hydrochloride liposome injection | Nanodrug | Topoisomerase inhibitor | Pancreatic cancer adjuvant therapy | Pivotal trial |
| Simmitinib hydrochloride tablets | Chemical drug | FGFR1-3&KDR&CSF1R multi-targeted small molecule kinase inhibitor | Esophageal squamous cell carcinoma | Pivotal trial |
| SYS6010 for injection | Biological drug | EGFR (ADC) | EGFR mutant non-small cell lung cancer | Pivotal trial |
| SYSA1801 injection | Biological drug | CLDN18.2 (ADC) | CLDN18.2-positive HER2-negative gastric adenocarcinoma | Pivotal trial |
| Valsartan levoamlodipine maleate tablets | Chemical drug | Angiotensin II receptor antagonist | Hypertension | Pivotal trial |

***Patents***

Since the beginning of 2024, the Group has filed 36 international PCT applications and 229 patent applications (127 domestic and 102 overseas), and has been granted 60 patents (31 domestic and 29 overseas). As of 30 September 2024, the Group has filed 198 international PCT applications and 2,023 patent applications (1,311 domestic and 712 overseas) in total and has been granted 959 patents (636 domestic and 323 overseas).

**Business Development**

***In-Licensing***

- In September 2024, the Group has entered into an exclusive license agreement with Jiangsu Alphamab to develop, sell, offer for sale and commercialise JSKN003 (a biparatopic HER2-targeting antibody-drug conjugate (ADC)) for the treatment of tumor-related indications in mainland China (excluding Hong Kong, Macau or Taiwan).

***Out-Licensing***

- In October 2024, the Group has entered into an exclusive license agreement with AstraZeneca for the global development, manufacture and commercialisation of the Group's Lipoprotein(a) (Lp(a)) inhibitor, YS2302018 and any pharmaceutical or biological product subsequently developed that is comprised of or contains YS2302018. The Group will receive an upfront payment of US$100 million and is also eligible to receive up to US$370 million in potential development milestone payments and up to US$1,550 million in potential sales milestone payments, plus tiered royalties.

**NON-HKFRS MEASURE**

For the purpose of assessing the performance of the Group, the Company has also presented the underlying profit attributable to shareholders as an additional financial measure, which is not required by, or presented in accordance with the Hong Kong Financial Reporting Standards ("HKFRS"). The Group believes that this non-HKFRS financial measure better reflects the underlying operational performance of the Group by eliminating non-operating items which the Group does not consider indicative of the Group's operational performance. However, the presentation of this non-HKFRS financial measure is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with HKFRS.

Additional information is provided below to reconcile the reported profit attributable to shareholders and the underlying profit attributable to shareholders.

| | **Nine months ended 30 September** | |
|---|---|---|
| | **2024** | 2023 |
| | ***(RMB'000)*** | *(RMB'000)* |
| **Reported profit attributable to shareholders** | **3,778,039** | 4,494,641 |
| Adjustments for: | | |
| — Fair value loss on financial assets measured at FVTPL *(note a)* | **54,843** | 88,932 |
| — Employee share-based compensation expense *(note b)* | **169,999** | 169,297 |
| — Gain on deemed disposal of partial interest in an associate | **–** | (32,861) |
| — Effect of corresponding income tax | **(4,092)** | (4,822) |
| **Underlying profit attributable to shareholders** | **3,998,789** | 4,715,187 |

*Notes:*

(a) Fair value changes on financial assets measured at FVTPL arise from the measurement of the Group's investments in certain partnerships, funds and listed equity securities at fair value.

(b) Out of the total employee share-based compensation expense recognised during the period, RMB148,469,000 (first nine months of 2023: RMB147,926,000) was in respect of share awards granted to selected employees of the Group by Key Honesty Limited, a shareholder of the Company.

## CONDENSED CONSOLIDATED INCOME STATEMENT

*For the nine months ended 30 September 2024 — Unaudited*

| | Nine months ended 30 September | |
|---|---|---|
| | **2024** | 2023 |
| | ***RMB'000*** | *RMB'000* |
| **Revenue** | **22,686,151** | 23,865,076 |
| Cost of sales | **(6,700,907)** | (7,072,976) |
| Gross profit | **15,985,244** | 16,792,100 |
| Other income | **401,531** | 464,997 |
| Other gains or losses, net | **(79,523)** | 22,158 |
| Selling and distribution expenses | **(6,624,661)** | (7,031,806) |
| Administrative expenses | **(880,646)** | (855,973) |
| Research and development expenses | **(3,879,728)** | (3,677,949) |
| Other expenses | **(62,441)** | (81,279) |
| Share of results of associates | **(39,532)** | (32,970) |
| Share of results of joint ventures | **(41,440)** | (5,503) |
| Gain on deemed disposal of partial interest in an associate | **–** | 32,861 |
| Finance costs | **(33,291)** | (16,877) |
| **Profit before tax** | **4,745,513** | 5,609,759 |
| Income tax expense | **(942,703)** | (964,743) |
| **Profit for the period** | **3,802,810** | 4,645,016 |
| **Profit for the period attributable to:** | | |
| Owners of the Company | **3,778,039** | 4,494,641 |
| Non-controlling interests | **24,771** | 150,375 |
| | **3,802,810** | 4,645,016 |
| | ***RMB cents*** | *RMB cents* |
| **Earnings per share** | | |
| — Basic | **32.03** | 37.84 |
| — Diluted | **32.03** | 37.83 |

## NOTES:

### 1. PRINCIPAL ACCOUNTING POLICIES

The principal accounting policies and methods of computation used in the preparation of the financial data for the nine months ended 30 September 2024 are consistent with those followed in the preparation of the Group's interim financial statements for the six months ended 30 June 2024.

### 2. REVENUE AND SEGMENT INFORMATION

| | Nine months ended 30 September | |
|---|---|---|
| | **2024** | 2023 |
| | ***RMB'000*** | *RMB'000* |
| Sales of goods | **22,686,151** | 23,830,376 |
| Licence fee income | **–** | 34,700 |
| | **22,686,151** | 23,865,076 |

Information reported to the executive directors, being the chief operating decision makers, for the purpose of resources allocation and assessment of segment performance focuses on types of goods delivered. The reportable segments of the Group are as follows:

(a) Finished drugs — research and development, manufacture and sale of pharmaceutical products and licence fee income;

(b) Bulk products — manufacture and sale of vitamin C and antibiotic products in bulk powder form; and

(c) Functional food and others — manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare services and others.

The following is an analysis of the Group's revenue and results by operating and reportable segment.

**Nine months ended 30 September 2024**

| | Finished drugs | Bulk products | | Functional food and others | Segment total | Eliminations | Consolidated |
|---|---|---|---|---|---|---|---|
| | | Vitamin C | Antibiotics | | | | |
| | *RMB'000* | *RMB'000* | *RMB'000* | *RMB'000* | *RMB'000* | *RMB'000* | *RMB'000* |
| SEGMENT REVENUE | | | | | | | |
| Sale of goods | **18,670,189** | **1,461,726** | **1,264,396** | **1,289,840** | **22,686,151** | **–** | **22,686,151** |
| Inter-segment sales | **–** | **29,814** | **145,563** | **124,519** | **299,896** | **(299,896)** | **–** |
| TOTAL REVENUE | **18,670,189** | **1,491,540** | **1,409,959** | **1,414,359** | **22,986,047** | **(299,896)** | **22,686,151** |
| SEGMENT PROFIT | **4,232,433** | **110,691** | **239,041** | **235,162** | | | **4,817,327** |
| Unallocated income | | | | | | | **222,276** |
| Unallocated expenses | | | | | | | **(179,827)** |
| Share of results of associates | | | | | | | **(39,532)** |
| Share of results of joint ventures | | | | | | | **(41,440)** |
| Finance costs | | | | | | | **(33,291)** |
| Profit before tax | | | | | | | **4,745,513** |

Nine months ended 30 September 2023

| | Finished drugs | Bulk products | | Functional food and others | Segment total | Eliminations | Consolidated |
|---|---|---|---|---|---|---|---|
| | | Vitamin C | Antibiotics | | | | |
| | *RMB'000* | *RMB'000* | *RMB'000* | *RMB'000* | *RMB'000* | *RMB'000* | *RMB'000* |
| SEGMENT REVENUE | | | | | | | |
| Sale of goods | 19,303,355 | 1,512,917 | 1,362,316 | 1,651,788 | 23,830,376 | – | 23,830,376 |
| Inter-segment sales | – | 5,664 | 243,739 | 213,627 | 463,030 | (463,030) | – |
| Licence fee income | 34,700 | – | – | – | 34,700 | – | 34,700 |
| TOTAL REVENUE | 19,338,055 | 1,518,581 | 1,606,055 | 1,865,415 | 24,328,106 | (463,030) | 23,865,076 |
| SEGMENT PROFIT | 4,959,021 | 51,528 | 103,584 | 439,527 | | | 5,553,660 |
| Unallocated income | | | | | | | 269,273 |
| Unallocated expenses | | | | | | | (190,685) |
| Share of results of associates | | | | | | | (32,970) |
| Share of results of joint ventures | | | | | | | (5,503) |
| Gain on deemed disposal of partial interest in an associate | | | | | | | 32,861 |
| Finance costs | | | | | | | (16,877) |
| Profit before tax | | | | | | | 5,609,759 |

Segment profit represents the profit earned by each segment without allocation of interest income, fair value changes on structured bank deposits, fair value changes on financial assets measured at FVTPL, central administrative expenses, share of results of associates and joint ventures, gain on deemed disposal of partial interest in an associate and finance costs. This is the measure reported to the executive directors for the purposes of resource allocation and performance assessment.

Inter-segment sales are charged at prevailing market rates.

## REVIEW OF RESULTS

The financial data for the nine months ended 30 September 2024 is based on the internal records and management accounts of the Group and has been reviewed by the audit committee of the Company but has not been reviewed or audited by the external auditor of the Company.

By order of the Board
**CSPC Pharmaceutical Group Limited**
**CAI Dongchen**
*Chairman*

Hong Kong, 15 November 2024

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*